Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence

Table 4 Rate of compliance¹ categoried by drop-out status n (%)

Drop-out status	Group B 160 mg/d (n = 56)	Group C 250 mg/d (n = 54)	P-value2
Drop-outs without recurrence	5	11	0.214
< 80% compliance	3 (60.0)	10 (90.9)
≥ 80% compliance	2 (40.0)	1 (9.1)
Non-withdrawal subjects	51	43	0.171
< 80% compliance	11 (21.6)	15 (34.9)
≥ 80% compliance	40 (78.4)	28 (65.1)

¹≥ 80% compliance denotes received ≥ 80% of required doses (12 doses/cycle × 9 cycles × 80);

²Fisher’s exact test.